Tomivosertib
Phase 1Active 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia
Trial Timeline
Sep 29, 2023 → Apr 23, 2030
NCT ID
NCT05744739About Tomivosertib
Tomivosertib is a phase 1 stage product being developed by eFFECTOR Therapeutics for Acute Myeloid Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT05744739. Target conditions include Acute Myeloid Leukemia.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05744739 | Phase 1 | Active |
Competing Products
20 competing products in Acute Myeloid Leukemia